.png)
Injectable Exosome Treatment in Australia: What Practitioners Need to Know About MCT
Why the source, preparation, route of administration and Australian regulatory framework matter when evaluating exosome-based treatments.
Exosome-based approaches are attracting growing interest in aesthetic and regenerative medicine. But one important distinction is often overlooked: not every product marketed around exosomes is designed for injection.
Many products available in the broader exosome market are formulated for topical or external use. MCT Meta Cell Technology takes a fundamentally different approach.
MCT is positioned by Athena Biomed and Meta Cell Technology as the world's only
injectable exosome technology, using photothermal biomodulation to generate autologous exosomes from the patient's own platelet-rich plasma (PRP).
That distinction matters clinically, scientifically and, particularly for Australian practitioners, from a regulatory perspective.
The more useful question is therefore not simply:
“Do exosomes work?”
It is:
“What exosomes are being used, where do they come from, how are they generated, how are they administered, what evidence supports them, and what regulatory framework applies?”
The Exosome Market Is Not One Category
Exosomes are small extracellular vesicles released by cells that participate in intercellular communication. They can carry biologically active molecules, including proteins, lipids and nucleic acids, which may influence recipient cells.
Research into extracellular vesicles has expanded rapidly across dermatology and regenerative medicine, with potential applications being investigated in skin regeneration, wound healing, inflammation and skin ageing.
But the word “exosome” does not describe a single treatment.
Products can differ according to:
Biological source
Preparation method
Composition
Intended use
Route of administration
Regulatory status
Clinical evidence
This is particularly important when comparing topical exosome products with injectable exosome approaches.
A topical product and an injectable preparation may both use the term “exosome”, but they are not automatically equivalent interventions.
The Key Distinction: Topical Exosomes vs Injectable Exosomes
The current exosome landscape includes products designed for external or topical application.
MCT is positioned differently. MCT is designed for injectable autologous exosome use
Athena Biomed describes MCT as “the only injectable exosome worldwide”, while Meta Cell Technology describes the system as a medical device platform for injectable autologous exosomes through photothermal biomodulation.
The distinction is important because MCT does not simply involve applying an exosome-containing formulation to the surface of the skin.
Instead, the system works with the patient's own biological material. The process begins with autologous PRP, which is then subjected to controlled photothermal biomodulation using the MCT System.
The resulting preparation contains autologous extracellular vesicles, including exosomes, which can then be used within an injectable clinical protocol.
This makes MCT fundamentally different from the concept of a conventional topical exosome product.
Why the Source Changes the Story
One of the first questions practitioners should ask about any exosome-based treatment is:
Where do the exosomes come from?
Exosomes can originate from different biological sources, and their biological characteristics can vary according to their source and production conditions.
MCT focuses on autologous exosomes generated from the patient's own PRP.
This means the biological material originates from the individual receiving the treatment.
The MCT approach therefore combines three important elements:
Autologous source → photothermal preconditioning → injectable exosome preparation
This is central to understanding what makes MCT different from many other exosome products discussed in aesthetic medicine.
What Makes PRP an Interesting Source of Exosomes?
PRP is an autologous biological material containing platelets and other components involved in tissue repair and cellular signalling.
Research into platelet-derived extracellular vesicles has contributed to growing interest in PRP as a potential source of biologically active vesicles.
This leads to an important question:
Can preconditioning influence what PRP releases?
This is one of the defining principles behind MCT.
The MCT System uses photothermal biomodulation, applying controlled light and thermal energy to autologous PRP.
The objective is to enhance the biological characteristics of the autologous preparation, including the release of extracellular vesicles. The research question is therefore more specific than simply asking whether exosomes may have regenerative potential.
It is:
Can controlled photothermal preconditioning of autologous PRP increase the release of extracellular vesicles and generate an injectable autologous exosome preparation?
This is the technological foundation behind MCT.
How MCT Creates an Injectable Autologous Exosome Preparation
MCT uses a defined workflow involving two medical devices.
The MCT Unit provides controlled photothermal biomodulation, while the MCT Kit is designed specifically for the processing of autologous material. Athena Biomed describes the MCT system as two certified medical devices designed to enhance autologous products such as PRP while releasing the patient's own exosomes.
The basic workflow is:
This workflow is what underpins MCT's positioning as an injectable autologous exosome technology, rather than a topical exosome product.
Inside the 2026 Facial Rejuvenation Study
The clinical relevance of this approach is beginning to appear in published research.
A 2026 pilot study by Vilà Rodríguez, Cordero and Pinto investigated facial rejuvenation using autologous exosomes released from preconditioned PRP with the MCT System.
The study enrolled 11 women with facial signs of ageing, with a mean age of 57 years. Nine participants completed the study.
Each participant received three treatment sessions.
The researchers evaluated outcomes using:
Ultrasonographic measurement of the subepidermal low-echogenic band (SLEB)
Compact stereophotogrammetric 3D imaging
Patient-reported assessment of skin appearance and improvement
One month after the final treatment, mean SLEB thickness was reduced by:
61.4% at the cheekbone
39.35% at the cheek
Additionally, 77.8% of participants reported an improvement in skin appearance. The treatment was reported as well tolerated.
These findings provide early clinical data for the use of autologous exosomes obtained from MCT-preconditioned PRP in facial rejuvenation.
However, this remains a small pilot study, with 11 participants enrolled and 9 completing the protocol.
The results should therefore be interpreted as preliminary clinical evidence rather than definitive evidence applicable to every patient population.
Beyond Before-and-After Photos: What SLEB Reveals
This is one of the more interesting details in the study. Aesthetic treatment outcomes are often presented through before-and-after photography, but the researchers also used ultrasound to measure the subepidermal low-echogenic band, or SLEB.
This provided an objective imaging-based measurement alongside 3D photography and patient-reported outcomes.
The combination is useful because these measurements capture different aspects of treatment response:
Imaging can provide measurable tissue changes.
3D photography can capture changes in facial surface characteristics.
Patient-reported outcomes capture the patient's own perception of improvement.
Together, they provide a broader picture than relying on a single visual assessment.
It’s Not Just About Adding Exosomes
It Is Not Just About Having Exosomes.The scientific interest in extracellular vesicles comes from their role in cell-to-cell communication, not simply from the presence of the word “exosome” on a product label.
Exosomes can carry biological cargo that may influence recipient cells, which is why researchers are investigating their potential involvement in tissue repair, regeneration and inflammatory processes.
For MCT, the concept is more specific.The objective is not simply to introduce exosomes into the skin. The approach is to:
That workflow is central to what differentiates MCT from topical exosome products.
Where the Current Evidence Actually Applies
The 2026 facial rejuvenation pilot study investigated patients with facial signs of ageing using autologous exosomes generated from MCT-preconditioned PRP.
The broader exosome literature covers a much wider range of potential applications, including skin regeneration, wound healing, scarring and inflammatory conditions.
However, evidence from one exosome source or preparation should not automatically be transferred to another.
The source, preparation process, route of administration, indication and study design all matter.
The key point:
“Exosome research” is not one evidence category.
MCT represents a specific approach within that broader field:
Autologous source + photothermal preconditioning + injectable administration.
The Australian Question: Where Does Regulation Come In?
For Australian practitioners, clinical evidence is only part of the picture. The regulatory question becomes particularly important when distinguishing topical exosome products from injectable exosome technologies.
The Therapeutic Goods Administration (TGA) explains that factors including ingredients, therapeutic claims and route of administration can be relevant when determining whether a product is a cosmetic or therapeutic good.
This means the fact that a product is marketed as an “exosome” product does not, by itself, establish its regulatory status.
Route of administration matters
A product intended for topical application and a system designed to generate an injectable preparation are not necessarily subject to the same regulatory considerations.
For Australian practitioners, this makes the injectable distinction particularly important.
MCT is specifically positioned as an injectable autologous exosome technology, rather than a topical exosome formulation. Athena Biomed describes it as the “only injectable exosome worldwide.”
That claim should be understood as the manufacturer's positioning of MCT within the global exosome market.
MCT and the Australian Regulatory Framework
The Australian regulatory position should be considered at the level of the specific technology, device, preparation and intended use.
The MCT System consists of two medical devices:
The MCT Unit is listed on the Australian Register of Therapeutic Goods (ARTG 514787) as a Class IIb medical device.
The MCT Kit is listed on the ARTG as a Class IIa medical device (ARTG 515734)
These registrations are important when discussing MCT in the Australian context.They establish that the specific MCT device components are included in the ARTG.
However, practitioners should distinguish this from saying that the TGA has separately approved “exosomes” as a standalone injectable therapeutic category.
The more precise statement is:
MCT is the world's only injectable exosome technology according to Athena Biomed and Meta Cell Technology, and its MCT Unit and MCT Kit are listed medical devices in the Australian ARTG.
This distinction allows the article to communicate MCT's unique market position without confusing device registration with approval of exosomes as a standalone drug or biological.
Why This Matters When Looking at the Australian Exosome Market
The word “exosome” is increasingly visible in aesthetic medicine. But practitioners should avoid assuming that every product marketed around exosomes represents the same clinical or regulatory category.
A topical exosome product may be intended for external application. An injectable autologous exosome workflow involves a different route of administration and a different preparation process.
MCT occupies a distinct position in this landscape because it is specifically designed around the generation of injectable autologous exosomes.
This is the central distinction practitioners should understand.
Topical exosome products
Generally involve an exosome-containing formulation intended for external application.
MCT injectable exosomes
Use the patient's own PRP as the biological source and employ photothermal biomodulation to generate an autologous exosome preparation intended for injectable use.
The two should not be treated as interchangeable simply because both use the term “exosome”
The Regulatory Question Is Also About the Preparation Process
The TGA's guidance concerning PRP, PRF and conditioned serum highlights the importance of factors such as processing, intended use, route of administration and applicable exemptions or exclusions.
For autologous preparations, the regulatory pathway can depend on the precise circumstances of collection, processing, manufacture and administration.
That makes the preparation workflow particularly relevant for MCT.
The practitioner should understand:
What biological material is collected?
How is the PRP prepared?
What processing occurs in the MCT System?
What biological material is produced?
How is it administered?
What is the intended clinical use?
Which regulatory requirements apply?
The regulatory question therefore should not be reduced to:
“Are exosomes approved?”
The more useful question is:
“What specific product or system is being used, what is its intended purpose, how is the preparation generated and administered, and what Australian regulatory framework applies?”
What Makes MCT Different?
MCT's distinction can be summarised in one clinical pathway:
This is fundamentally different from a topical product simply containing or being marketed around exosomes.
It is also why MCT is positioned as the world's only injectable exosome technology by Athena Biomed and Meta Cell Technology.
The distinction is not simply the presence of exosomes. It is the combination of autologous sourcing, photothermal processing and injectable application.
Promising Early Data, But What Are We Still Missing?
The 2026 facial rejuvenation study provides early clinical data, but several questions remain.
The study involved:
11 enrolled participants
9 study completers
All participants were women
Three treatment sessions
Assessment one month after the final treatment
The study also involved authors affiliated with Meta Cell Technology, with those affiliations and disclosures reported in the publication.
Further research is needed to determine:
Whether the findings are reproducible in larger populations
How long observed changes persist
How outcomes compare with other regenerative approaches
Which patient populations may benefit most
How treatment protocols can be standardised
How injectable autologous exosome approaches should be integrated into broader clinical practice
These evidence gaps do not negate the findings of the pilot study.
They define what still needs to be investigated.
Before Considering an Injectable Exosome Approach: 5 Questions Worth Asking
Rather than asking only “Do exosomes work?”, practitioners can use a more specific framework.
Question | What to assess | Why it matters |
1. What is the source? | Is the exosome preparation autologous or derived from another biological source? | The biological source can influence the composition, characteristics and regulatory classification of the preparation. |
2. How is it generated? | What preparation, processing or conditioning method is used to generate the product? | Different production and processing methods can result in substantially different biological preparations, making it important to assess the actual technology rather than treating all exosome products as equivalent. |
3. Is it topical or injectable? | What is the route of administration? | Route of administration is a fundamental distinction that can affect the clinical application, safety considerations, evidence requirements and regulatory framework. |
4. What evidence supports this specific technology? | Is there clinical evidence for the actual source, preparation method, route of administration and indication being discussed? | General exosome research does not necessarily validate a specific product or technology. Evidence should be assessed against the exact technology and intended clinical use. |
5. What regulatory framework applies in Australia? | What is the product's ARTG status, intended purpose, route of administration, preparation process and applicable regulatory requirements? | Australian regulatory requirements depend on the specific product and how it is manufactured, supplied and intended to be used. Regulatory status should therefore be assessed on the individual technology rather than inferred from the broader exosome category. |
For MCT, the MCT Unit and MCT Kit are listed medical devices in the ARTG, while published clinical research has investigated injectable autologous exosomes generated using the MCT System.
The Clinical Takeaway
Exosome-based regenerative medicine is a rapidly developing field, but “exosome treatment” is not one standardised intervention.
The biological source, preparation method, route of administration, clinical indication and evidence all matter.
MCT takes a specific approach: it uses autologous PRP and photothermal biomodulation to generate autologous exosomes for injectable use.
Athena Biomed and Meta Cell Technology position MCT as the world's only injectable exosome technology, distinguishing it from the broader market of topical exosome products.
The 2026 facial rejuvenation pilot study provides early clinical evidence for this approach, reporting changes in SLEB thickness and patient-reported skin appearance following treatment with autologous exosomes generated using the MCT System.
For Australian practitioners, the regulatory conversation is equally important. The MCT Unit and MCT Kit are listed in the Australian Register of Therapeutic Goods as medical devices, while the clinical use of the resulting autologous preparation needs to be understood within the applicable Australian regulatory framework.
The key questions are therefore:
What exosomes?From where?Produced how?Delivered by what route?Supported by what evidence?And under what Australian regulatory framework?
For MCT, those questions lead to a clearly differentiated proposition:
MCT is the world's only injectable exosome technology, generating autologous exosomes from the patient's own PRP through photothermal biomodulation.
Ready to Explore MCT™ Beyond the Research?
Understanding the science is one part of evaluating an emerging injectable exosome approach. Seeing how the MCT™ workflow works in practice is another.
From autologous PRP and photothermal biomodulation to the generation of autologous exosomes for injectable applications, MCT™ brings these steps together within a defined clinical workflow.
Book an MCT™ Demo to explore the technology, understand the workflow, and learn more about how MCT™ may fit into your clinical practice.
For healthcare professionals only. Clinical use should follow applicable local regulatory requirements and professional guidelines.
References
Vilà Rodríguez D, Cordero L, Pinto H. Facial rejuvenation with autologous exosomes released from preconditioned platelet-rich plasma using the Meta Cell Technology System: A pilot study. Dermatology Online Journal. 2026;32(2). DOI: 10.25251/b5kf0v44.
Yu H, et al. Exosomes: The emerging mechanisms and potential clinical applications in dermatology. International Journal of Biological Sciences. 2024;20(5):1778–1795.
Therapeutic Goods Administration (TGA). Determining if your product is a cosmetic or therapeutic good.
Meta Cell Technology. MCT Publications and Scientific Evidence.
